Unknown

Dataset Information

0

Tofacitinib Versus Non-Tumor Necrosis Factor Biologics for Patients With Active Rheumatoid Arthritis.


ABSTRACT: Objectives:This study aims to compare the disease status of patients with active rheumatoid arthritis (RA) after treatment with tofacitinib or non- tumor necrosis factor (TNF) biologics. Patients and methods:The study included a total of 50 RA patients (18 males, 32 females; mean age 68.3±1.3 years; range 42 to 92 years). We prospectively and randomly enrolled 25 patients for treatment with tofacitinib (Tofa group: 10 males, 15 females; mean age 68.3±2.0 years; range, 42 to 92 years) and 25 for treatment with non-TNF biologics (non-TNF group: 8 males, 17 females; mean age 68.3±1.7 years; range 51 to 92 years). Mean disease activity score 28 (DAS28), C-reactive protein (CRP), clinical disease activity index (CDAI), health assessment questionnaire (HAQ)-disability index (DI), and matrix metalloproteinase-3 values were recorded at baseline and at 4, 8, and 12 months. Results:There was a significant difference in the percent changes of DAS28, CRP and CDAI at every time point versus baseline in both treatment groups. HAQ-DI was also significantly different at every time point in both groups except for at four months in the non-TNF group. Conclusion:Tofacitinib was well tolerated in active RA patients and exerted effects comparable to those of non-TNF biologics.

SUBMITTER: Nakamura Y 

PROVIDER: S-EPMC6117139 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tofacitinib Versus Non-Tumor Necrosis Factor Biologics for Patients With Active Rheumatoid Arthritis.

Nakamura Yukio Y   Suzuki Takako T   Yamazaki Hideshi H   Kato Hiroyuki H  

Archives of rheumatology 20171013 2


<h4>Objectives</h4>This study aims to compare the disease status of patients with active rheumatoid arthritis (RA) after treatment with tofacitinib or non- tumor necrosis factor (TNF) biologics.<h4>Patients and methods</h4>The study included a total of 50 RA patients (18 males, 32 females; mean age 68.3±1.3 years; range 42 to 92 years). We prospectively and randomly enrolled 25 patients for treatment with tofacitinib (Tofa group: 10 males, 15 females; mean age 68.3±2.0 years; range, 42 to 92 yea  ...[more]

Similar Datasets

| S-EPMC9314478 | biostudies-literature
| S-EPMC6858427 | biostudies-literature
| S-EPMC6527918 | biostudies-literature
| S-EPMC7296929 | biostudies-literature
| S-EPMC9606533 | biostudies-literature
| S-EPMC5573926 | biostudies-literature
| S-EPMC6207907 | biostudies-literature
| S-EPMC5327780 | biostudies-literature
| S-EPMC2745801 | biostudies-literature